Article Text

Download PDFPDF
CP-134 Analysys of therapeutic response and tolerability in patients treated with crizotinib in ALK positive NSCLC
  1. M Tonelli,
  2. M Scaldaferri,
  3. D Barilà,
  4. A Bianco,
  5. M Ferroni,
  6. G Valinotti,
  7. E Caiazza,
  8. S Bordignon,
  9. D Martinetto,
  10. F Cattel
  1. A. O. U. San Giovanni Battista, Pharmacy, Turin, Italy


Background Anaplastic lymphoma kinase (ALK) is a validated tyrosine kinase target in several cancers. Crizotinib is indicated for the treatment of adults with previously treated ALK positive advanced non-small cell lung cancer (NSCLC), which is a distinct molecular subtype of NSCLC.

Purpose Evaluation of the therapeutic efficacy and tolerability of crizotinib in a cohort of 16 previously treated ALK positive advanced NSCLC patients.

Material and methods Evaluation of data from medical records and Italian ‘Registro dei Farmaci AIFA’.

Results 56% of patients were female, mean age at diagnosis was 52.5 years and 62.5% were smokers. The histological type was adenocarcinoma for all patients, and 81.25% presented with NSLC stage IV. 93% of patients had previously received platinum based chemotherapy and 18.75% underwent radiotherapy for metastatic disease. Time elapsed between diagnosis and the first treatment with crizotinib was 15.5 months (range 2–101.5). The average treatment duration with crizotinib was 4.2 months with a median dose of 473 mg/day due to interruptions during therapy. The end of treatment was due to progression of disease in 54.54% of cases, in 18.2% to toxicity and not valued in 27.3%; in 9.09% of patients the better response during treatment was assessed as partial response, in 45.45% as stable disease and in 45.45% was not valued. Liver toxicity (rise in liver enzymes: ALT 1106, AST 639), gastrointestinal toxicity and dysgeusia were reported in 4 patients (36.4%). 82% of patients were treated with subsequent therapy, while 27.3% entered Named Patient Programmes for ceritinib and alectinib.

Conclusion Presently, our experience in the treatment of NSCLC with crizotinib is based on a small number of patients. The results showed good tolerance towards the drug. However, this proved to be not effective.

References and/or Acknowledgements

  1. Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94

References and/or AcknowledgementsNo conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.